[Study methods of drugs in Alzheimer disease].
The availability of new drugs for Alzheimer's disease, with different pharmacological profiles, leads to a redefinition the relevant methodology for developing drugs in this indication, including the inclusion/exclusion criteria, the duration of the studies, and therefore, the relevant guidelines. This was the purpose of the Giens Round-table devoted to the new methodology for drug development in Alzheimer disease.
Dubois
B
B
Fédération de Neurologie, Hôpital Salpêtrière 47 Bd de l'hôpital, Paris, France.
Stehlé
B
B
Lehner
J P
JP
Derouesné
C
C
Bourin
M
M
Lamour
Y
Y
Blin
O
O
Jourdain
G
G
Alperovitch
A
A
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000818:Animals; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D004341:Drug Evaluation; D005602:France; D017408:Guidelines as Topic; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use
D018696:Neuroprotective Agents
Méthodes d'étude des médicaments dans la maladie de l'Alzheimer.